Similarly, a PGC-1α activator enhanced CD8+ T-cell activity and augmented PD-1 blockade efficacy, thereby reducing tumour volume in mouse models of colon cancer [246], suggesting a potential druggable target of TME metabolism that could improve immunosuppression and complement ICB therapy. The gene discussed is CD8A; the disease is malignant colon neoplasm.